|By Marketwired .||
|July 17, 2014 01:32 PM EDT||
RYE BROOK, NY -- (Marketwired) -- 07/17/14 -- CBLPath, a Sonic Healthcare USA laboratory, is pleased to announce the launch of its new cytogenetics division and the appointment of Murty V. Vundavalli, Ph.D., to Consulting Director for the division. The new division, which will be based out of CBLPath's headquarters in Rye Brook, NY, is licensed through New York State and will initially focus on hematologic cancers. The company's plan is to eventually expand the division's offerings to include additional tests for other conditions/diseases in the future. The new line of hematologic tests that the division now offers further expands CBLPath's extensive in-house testing capabilities.
Dr. Murty V. Vundavalli is an expert in the field of cancer cytogenetics with more than 30 years of experience. He is the Director for the Cancer Cytogenetics Laboratory at New York Presbyterian Hospital/Columbia University Medical Center and has published more than 150 articles, book chapters and reviews. He also serves as the current Executive Editor for Molecular Cancer.
According to statistics published by the Leukemia & Lymphoma Society, an estimated 150,000 patients in the U.S. will be diagnosed with some form of hematologic cancer in 2014. Cytogenetics takes a broad look at a patient's chromosomes and is capable of detecting a variety of different abnormalities, such as chromosome gains, losses or translocations. For hematologic (blood) cancers, cytogenetics testing plays a role in both the diagnosis of specific diseases and in assessing prognosis for a given leukemia or lymphoma. In addition to the diagnosis, the prognostic risk stratification information provided by the test can help guide treatment decisions and aid in patient counseling.
One of the greatest strengths of the new division will be its ability to deliver faster turnaround times for its tests. In an effort to deliver critical results to physician and patients as quickly as possible, an exhaustive examination of each step of the testing process was conducted during the initial planning stages for the division. The goal of this effort was to streamline and accelerate the overall process for analyzing and delivering results. After removing inefficiencies and implementing a lean laboratory process, the division is now poised to deliver test results with turnaround times that are superior to the industry standard.
"The addition of in-house cytogenetics testing will allow CBLPath to provide its physician-customers with vital information about their patient's disease with turnaround time that is better than what most labs in the industry can provide," said CBLPath Co-CEO and Chief Medical Officer, Dr. Carlos D. Urmacher, FCAP, FASCP. "We remain committed to helping our clients deliver better medicine, faster."
To speak with a local CBLPath representative about ordering cytogenetics testing, call 877.225.7284. To see the company's entire array of tests, visit www.CBLPath.com and click the Test Menu link.
CBLPath, a Sonic Healthcare USA laboratory, is a leading pathology services provider, combining anatomic pathology with advanced molecular diagnostics, esoteric testing and digital pathology. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. We integrate comprehensive diagnostic, prognostic and theranostic testing to deliver personalized medicine and we provide our subspecialty physician clients timely, accurate results enabling the most effective patient care. For more about the company, please visit CBLPath.com.
Documents and/or Photos available for this release:
pdf of CBLPath cytogenetics press release
To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 375811
Mar. 29, 2017 01:30 PM EDT Reads: 1,719
Mar. 29, 2017 01:30 PM EDT Reads: 513
Mar. 29, 2017 01:30 PM EDT Reads: 2,234
Mar. 29, 2017 12:45 PM EDT Reads: 671
Mar. 29, 2017 12:15 PM EDT Reads: 7,873
Mar. 29, 2017 12:00 PM EDT Reads: 628
Mar. 29, 2017 11:45 AM EDT Reads: 2,561
Mar. 29, 2017 11:30 AM EDT Reads: 630
Mar. 29, 2017 11:00 AM EDT Reads: 3,417
Mar. 29, 2017 10:53 AM EDT Reads: 192
Mar. 29, 2017 10:45 AM EDT Reads: 10,463
Mar. 29, 2017 10:15 AM EDT Reads: 1,704
Mar. 29, 2017 10:00 AM EDT Reads: 2,330
Mar. 29, 2017 08:45 AM EDT Reads: 930
Mar. 29, 2017 08:00 AM EDT Reads: 7,516